Literature DB >> 11918506

The economic burden of Barrett's esophagus in a Medicaid population.

Mayur M Amonkar1, Iftekhar D Kalsekar, J Gregory Boyer.   

Abstract

OBJECTIVE: To estimate the overall healthcare expenditures of patients with Barrett's esophagus in the West Virginia Medicaid population.
METHODS: West Virginia Medicaid-paid claims data for the period January 1, 1995, to December 31, 1999, were used for the study. The population included all individuals eligible for West Virginia Medicaid during the study period except for Medicare eligible- and Medicaid managed-care recipients. A prevalence-based approach was used to determine the cost of illness for Barrett's esophagus.
RESULTS: The total cost of illness for Barrett's esophagus more than tripled, from $182399 in 1995 to $623864 in 1999, with approximately a 4(1/2)-fold increase in medical and more than a threefold increase in pharmacy costs. The average cost of treating Barrett's esophagus was found to be approximately $1207 per patient in 1999. Overall, pharmacy costs accounted for >66% of the total costs. Controlling for age, gender, and number of comorbidities, patients with Barrett's esophagus incur 21.2% higher overall costs than patients with gastroesophageal reflux disease and 62.4% higher overall costs than the general Medicaid population.
CONCLUSIONS: The increasing prevalence of and resource utilization for Barrett's esophagus provide a framework for further analysis and implementation of policies aimed at appropriate allocation of resources for the state's Medicaid program.

Entities:  

Mesh:

Year:  2002        PMID: 11918506     DOI: 10.1345/aph.1A309

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  5 in total

1.  Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium.

Authors:  Prateek Sharma; David A Katzka; Neil Gupta; Jaffer Ajani; Navtej Buttar; Amitabh Chak; Douglas Corley; Hashem El-Serag; Gary W Falk; Rebecca Fitzgerald; John Goldblum; Frank Gress; David H Ilson; John M Inadomi; Ernest J Kuipers; John P Lynch; Frank McKeon; David Metz; Pankaj J Pasricha; Oliver Pech; Richard Peek; Jeffrey H Peters; Alessandro Repici; Stefan Seewald; Nicholas J Shaheen; Rhonda F Souza; Stuart J Spechler; Prashanth Vennalaganti; Kenneth Wang
Journal:  Gastroenterology       Date:  2015-08-19       Impact factor: 22.682

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Enrollment factors and bias of disease prevalence estimates in administrative claims data.

Authors:  Elizabeth T Jensen; Suzanne F Cook; Jeffery K Allen; John Logie; Maurice Alan Brookhart; Michael D Kappelman; Evan S Dellon
Journal:  Ann Epidemiol       Date:  2015-03-21       Impact factor: 3.797

Review 4.  Health-related quality of life in patients with Barrett's esophagus: a systematic review.

Authors:  Seth D Crockett; Quinn K Lippmann; Evan S Dellon; Nicholas J Shaheen
Journal:  Clin Gastroenterol Hepatol       Date:  2009-03-10       Impact factor: 11.382

Review 5.  Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy.

Authors:  Devidas Menon; Tania Stafinski; Heng Wu; Darren Lau; Clarence Wong
Journal:  BMC Gastroenterol       Date:  2010-09-27       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.